Preclinical pipeline

Adenosine Pathway Inhibitor

iTeos’ scientists identified a new mechanism that modulates T cell activation and proliferation in high adenosine concentration and is additive to A2A antagonist. A drug discovery program is currently ongoing to identify preclinical drug candidates for this new mechanism.